Skip to content

Whooping cough (pertussis) vaccine - Whooping cough vaccine information for health and social care professionals

ADACEL® and the quadrivalent (4-in-1) are inactivated (not live vaccines) and thiomersal-free. As inactivated vaccines contain no live organisms, they cannot replicate and cannot cause infection to the mother or the foetus. These vaccines are usually highly effective and have excellent safety records.  

The 4-in-1 will continue to be the vaccine used for the pre-school booster vaccination of children, and for the prenatal vaccination of pregnant women for whom ADACEL® is contra-indicated (e.g., due to a history of anaphylactic allergy to latex). 

Pregnancy immunisations 

Timing of vaccine administration in pregnancy 

The pertussis vaccine is offered to all pregnant women from 16 weeks of pregnancy. It is ideally offered between 16 and 32 weeks of pregnancy to maximise the likelihood the baby will be protected from birth. The vaccine can be given after 32 weeks, but as the body needs time to make antibodies to be passed on to the unborn baby, it may not give the baby the same level of protection. Pregnant women require vaccination in each pregnancy.   

Women who did not receive the pertussis vaccine in their pregnancy can still receive it in the two months following birth (until the child receives their first dose of pertussis-containing vaccine). This will protect the woman and may prevent her from becoming a source of infection for the baby, although it will not provide direct protection of the baby. There is no evidence of risk from vaccinating breast-feeding women with the pertussis vaccine.   

Change in vaccine product for pregnant women 

Currently, there is no monovalent pertussis vaccine available. In October 2022, the JCVI advised a non-IPV containing pertussis vaccine (Tdap) in the maternal programme to address a potential immunity gap. Since the 1st of July 2024, the pertussis-containing vaccine for pregnant women switched from the dTaP/IPV quadrivalent (Boostrix-IPV®) to a trivalent vaccine containing tetanus, diphtheria and pertussis (Tdap) called ADACEL®.  

Like Boostrix- IPV®, ADACEL® contains the lower doses of pertussis, diphtheria and tetanus, but it does not contain the polio component found in Boostrix-IPV®. However, Boostrix-IPV® (or Repevax®) may still be administered if ADACEL® is unavailable or contraindicated.

Research indicates that infants of mothers vaccinated with dTaP/IPV vaccines during pregnancy had lower, but still protective, polio antibody levels compared to infants of unvaccinated mothers.  

Baby and childhood immunisations 

Pertussis-containing vaccination in babies and children is offered with the 6-in-1 (DTaP/IPV/Hib/HepB) vaccine and the 4-in-1 (DTaP/IPV) booster at appropriate intervals according to the NHS routine childhood vaccination schedule for Wales.

Healthcare workers 

Healthcare workers can be an important source of infection to vulnerable infants. Those with direct contact with pregnant women or infants, who have not received a pertussis-containing vaccine in the last 5 years, are eligible for a pertussis-containing vaccine as part of their occupational healthcare. For further information, visit the link below. 

The routine immunisation schedules for Wales contains information about routine and non-routine vaccinations. 

Summary of product characteristics  

Schedule guidance in the Green Book chapter 24 Pertussis on the UK Government website (external site) supersedes the SmPC.  

Guidance  

Vaccination programme recommendations from the Joint Committee on Vaccination and Immunisation (JCVI) and Welsh Government policy can be found at the links below.  

Joint Committee on Vaccination and Immunisation on the UK Government website (external site) - read JCVI publications and statements: search e.g., pertussis.

Welsh Health Circulars and Welsh Government letters 

Clinical resources and information 

Patient group directions (PGDs) and protocols  

Resources

Data and surveillance 

Vaccination surveillance information can be found on the pages below:  

Page last reviewed: 15th August 2025